Shanghai Pharmaceuticals Holding Stock Revenue
| S1R Stock | EUR 1.58 0.01 0.63% |
Shanghai Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Shanghai Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Pharmaceuticals stock.
Shanghai |
Shanghai Pharmaceuticals Holding Company Revenue Analysis
Shanghai Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Shanghai Pharmaceuticals Revenue | 215.82 B |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Shanghai Pharmaceuticals Holding reported 215.82 B of revenue. This is much higher than that of the Healthcare sector and 170.75% higher than that of the Medical Distribution industry. The revenue for all Germany stocks is significantly lower than that of the firm.
Shanghai Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics of similar companies.Shanghai Pharmaceuticals is rated fifth in revenue category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 8.94 B | |||
| Shares Outstanding | 919.07 M | |||
| Shares Owned By Insiders | 22.00 % | |||
| Shares Owned By Institutions | 32.12 % | |||
| Price To Earning | 6.59 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 215.82 B | |||
| Gross Profit | 28.41 B | |||
| EBITDA | 10.73 B | |||
| Net Income | 5.09 B | |||
| Cash And Equivalents | 23.68 B | |||
| Cash Per Share | 8.33 X | |||
| Total Debt | 7.16 B | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 1.23 X | |||
| Book Value Per Share | 17.90 X | |||
| Cash Flow From Operations | 5.06 B | |||
| Earnings Per Share | 0.23 X | |||
| Price To Earnings To Growth | 2.42 X | |||
| Number Of Employees | 47.06 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 9.17 B | |||
| Total Asset | 163.44 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 2.74 % | |||
| Net Asset | 163.44 B | |||
| Last Dividend Paid | 0.42 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.